AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03454035
Drug: Ulixertinib
RxNorm normalized name: Ulixertinib
DrugBank: Ulixertinib (DB13930)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulixertinib 300mg, orally, twice a day concomitantly with palbociclib
Trial: NCT02648633
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 mg/kg of nivolumab will be administered through IV infusion every two weeks following stereotactic radiosurgery.
Trial: NCT02648633
Drug: Valproate
RxNorm normalized name: Valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will begin regimen of valproate prior to radiosurgery and continue to receive therapy concurrently with nivolumab. Subjects will receive valproate daily with a target serum level of 75-100 μg/ml.
Trial: NCT00507728
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)
Trial: NCT03454035
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Palbociclib 125mg, orally, once a day concomitantly with ulixertinib
Trial: NCT03159897
Drug: Bleomycin
RxNorm normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bleomicina Comparator arm: cycle 1-2 (and eventually 3-6): 10,000 units/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 10,000 units/m2 i.v. days 1,11. Cycles 5 and 6: 10,000 units/m2 i.v. days 1,11.
Trial: NCT00507728
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)
Trial: NCT03159897
Drug: Vinblastine
RxNorm normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinblastina Comparator arm: cycle 1-2 (and eventually 3-6): 6 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 6 mg/m2 i.v. days 1,11. Cycles 5 and 6: 6 mg/m2 i.v. days 1,11.
Trial: NCT03159897
Drug: Dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazina Comparator arm: cycle 1-2 (and eventually 3-6): 375 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 375 mg/m2 i.v. days 1,11. Cycles 5 and 6: 375 mg/m2 i.v. days 1,11.
Trial: NCT00724880
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel is stopped 5 days prior to surgery
Trial: NCT00724880
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel is stopped 3 days prior to surgery
Trial: NCT00724880
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel is stopped 0 days prior to surgery
Trial: NCT01303003
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.
Trial: NCT02341573
Drug: leukotriene receptor antagonist and bronchial relaxant
RxNorm normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At the acute stage of asthma : etinoline,twice a day for 7 days; At the remission stage: Singulair, once daily for 3 months.
Trial: NCT02504060
Drug: N-acetyl-D-glucosamine
RxNorm normalized name: N-Acetyl-D-glucosamine
DrugBank: N-Acetylglucosamine (DB00141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03249662
Drug: bupivacaine 100 mg
RxNorm normalized name: BUPivacaine 100 mg parenteral implant
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupivacaine 100 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
Trial: NCT04365127
Drug: Progesterone 100 MG
RxNorm normalized name: progesterone 100 MG
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous administration twice daily
Trial: NCT03707028
Drug: Rivoceranib
RxNorm normalized name: Rivoceranib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT03707028
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution administered intravenously
Trial: NCT00096473
Drug: Donepezil hydrochloride
RxNorm normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00880867
Drug: Poly-ICLC
RxNorm normalized name: Poly-ICLC
DrugBank: Hiltonol (DB17293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An accessible site of disease (lymph node, cutaneous, subcutaneous, etc.) will be selected by the principal investigator. Patients will then receive two doses of low dose irradiation (2 Gy per day) to that single site on days 1 and 2. Intratumorally or peritumorally Poly-ICLC will be dosed on days 3 and 4 by the physician during weeks 1, 2, 3, 4, and 8.
Trial: NCT02786810
Drug: Sulfur hexafluoride type-a lipid microspheres
RxNorm normalized name: Protein-type A microspheres
DrugBank: Sulfur hexafluoride (DB11104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Used as a contrast to enhance renal ultrasound
Trial: NCT04132102
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib is a member of the second generation TKIs, which binds irreversibly to the erbB family of receptors. Afatinib will be administrated orally with the starting dose of 40 mg tablets, once per day. If patients can't tolerate drug related AEs with 40mg, patients can receive 30mg once per day after AEs recovered to Grade 0-1.
Trial: NCT00798707
Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg tablet, once daily dosing for 8 weeks
Trial: NCT00798707
Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg tablet, once daily dosing for 8 weeks
Trial: NCT00107809
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03395119
Drug: Ozone
RxNorm normalized name: OZONE
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the four-week supplementation period, each subject will be blindly exposed on consecutive days to filtered air for 2 hours and to 0.3 ppm ozone for 2 hours, while undergoing intermittent moderate exercise (minute ventilation of 20 L/min/m²).
Trial: NCT00339066
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03256526
Drug: PF-06835919 Low Dose
RxNorm normalized name: ethinyl estradiol
DrugBank: PF-06835919 (DB19163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg once daily
Trial: NCT03256526
Drug: PF-06835919 High Dose
RxNorm normalized name: PF-06835919
DrugBank: PF-06835919 (DB19163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg once daily
Trial: NCT05631769
Drug: Dual antiplatelet agent duration
RxNorm normalized name: Tums Dual Action
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who receive percutaneous coronary intervention for coronary artery disease will be randomized to arms with different DAPT strategies.~The randomization will be stratified according to the High bleeding risk (defined according to the ARC-HBR criteria).
Trial: NCT03467152
Drug: Irsenontrine
RxNorm normalized name: Irsenontrine
DrugBank: Irsenontrine (DB19044)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hypromellose capsules.
Trial: NCT02117128
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02639026
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg every 4 weeks for 4 doses
Trial: NCT04849858
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in this group will receive a TAP block using the drug Bupivacaine.
Trial: NCT04849858
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in this group will receive a TAP block using the drug Liposomal Bupivacaine.
Trial: NCT04849858
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in this group will receive a TAP block using the drug Liposomal Bupivacaine followed by a re-dosing during their hospitalization
Trial: NCT03280563
Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be given as 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle. This regimen will apply to all arms except when given with entinostat in Stage 1, or exemestane or tamoxifen in Stage 2, in which atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle.
Trial: NCT03280563
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 15 of each 28-day cycle in the regimen containing fulvestrant. When given with exemestane or tamoxifen, bevacizumab will be given as 15 mg/kg via IV infusion on Day 1 of each 21-day cycle.
Trial: NCT03280563
Drug: Entinostat
RxNorm normalized name: entinostat
DrugBank: Entinostat (DB11841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entinostat will be given as 5 mg orally once a week on Days 1, 8 and 15 of each 21-day cycle.
Trial: NCT03280563
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane will be given as 25 mg orally QD in each 21-day cycle.
Trial: NCT03280563
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant will be given as 500 mg intramuscularly on Days 1 and 15 of Cycle 1 and thereafter on Day 1 of each 28-day cycle.
Trial: NCT03280563
Drug: Ipatasertib
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipatasertib will be given as 400 mg orally QD on Days 1-21 of each 28-day cycle.
Trial: NCT03280563
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen will be given as 20 mg orally QD in each 21-day cycle.
Trial: NCT03280563
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Abemaciclib will be given as 150mg twice daily during each 28-day cycle.
Trial: NCT00929201
Drug: Sitagliptin phosphate/metformin hydrochloride FDC
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose sitagliptin/metformin 50/500 mg FDC tablet after consumption of a high-fat meal in one of two treatment periods.
Trial: NCT00929201
Drug: Sitagliptin phosphate
RxNorm normalized name: Sitagliptin Phosphate
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose sitagliptin 50 mg tablet after consumption of a high-fat meal in one of two treatment periods.
Trial: NCT00929201
Drug: Metformin hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose metformin 500 mg tablet after consumption of a high-fat meal in one of two treatment periods.
Trial: NCT01224418
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03722849
Drug: Adenosine Triphosphate
RxNorm normalized name: Adenosine triphosphate
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will inhale escalating concentrations of Adenosine Triphosphate (ATP) to induce cough and the urge-to-cough
Trial: NCT03722849
Drug: Capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will inhale escalating concentrations of capsaicin to induce cough and the urge-to-cough
Trial: NCT00828438
Drug: Lorcaserin 10mg
DrugBank: Lorcaserin (DB04871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00996008
Drug: CT 327
RxNorm normalized name: CT 179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g CT 327 cream will be applied to 2 target lesions twice daily 0.5 g placebo cream will be applied to remaining 2 target lesions twice daily
Trial: NCT00034359
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00547209
Drug: air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60% air combined with 40% oxygen for ventilation
Trial: NCT00547209
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60% nitrous oxide combined with 40% oxygen for ventilation
Trial: NCT01917877
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
Trial: NCT01917877
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
Trial: NCT03978143
Drug: Treatment C
RxNorm normalized name: Acne Treatment Cream
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 250 mg crizotinib dose as FC formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
Trial: NCT03978143
Drug: Treatment D
RxNorm normalized name: Earwax Treatment Drops
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single 250 mg crizotinib dose as OS will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
Trial: NCT03978143
Drug: Treatment E
RxNorm normalized name: Benzoyl Peroxide 10% Topical application Cream [ACNE TREATMENT EXTRA STRENGTH]
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg crizotinib as cMS1 formulation will be administered with high-fat, high-calorie meal after an overnight fast of at least 10 hours.
Trial: NCT03978143
Drug: Treatment F
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg crizotinib as cMS2 will be administered with a high-fat, high-calorie meal after an overnight fast of at least 10 hours.
Trial: NCT00732901
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram: once daily 10 mg on days 1-3, 20 mg on days 4-24 and 10 mg on days 25-28
Trial: NCT01596556
Drug: Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: both groups will be given nicotine lozenges before a VO2 test and a HTT.
Trial: NCT00853268
Drug: Controlled-Release Oxycodone Hydrochloride 40 mg
RxNorm normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Controlled-Release Oxycodone Hydrochloride 40 mg, single dose with food
Trial: NCT04404530
Drug: Palynziq
RxNorm normalized name: Palynziq
DrugBank: Pegvaliase (DB12839)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will take Palynziq as prescribed by their genetics doctor. In accordance with the Palynziq Risk Evaluation and Mitigation Strategy (REMS) protocol, patients will have their first injection of Palynziq at the Emory Genetics Clinic under the supervision of a physician. After initiating therapy, patients will continue to mail in blood spot filter papers and 3-day dietary records to their clinic providers as standard components of clinical care.
Trial: NCT01002820
Drug: ganaxolone
RxNorm normalized name: ganaxolone
DrugBank: Ganaxolone (DB05087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: liquid suspension, 50 mg/mL, up to 500 mg/day TID or 1500 mg/day, up to 1 year
Trial: NCT02623231
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
Trial: NCT02206256
Drug: Omega-3 fatty acid capsules
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 times a day 1 capsule for 4 weeks before gastric bypass surgery
Trial: NCT00826865
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 750 mg tablet
Trial: NCT00085826
Drug: Exisulind
RxNorm normalized name: Exisulind
DrugBank: Exisulind (DB06246)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01170767
Drug: Avastin
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection of bevacizumab at a concentration of 1.25 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
Trial: NCT01170767
Drug: Lucentis
RxNorm normalized name: Lucentis
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection of ranibizumab at a concentration of 0.50 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
Trial: NCT04469465
Drug: Danicopan
RxNorm normalized name: Danicopan
DrugBank: Danicopan (DB15401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT04469465
Drug: C5 Inhibitor
RxNorm normalized name: Complement c5 inhibitory humanized recycling monoclonal antibody (rg-6107 )
DrugBank: Crovalimab (DB16128)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will continue to receive their ongoing C5 inhibitor (eculizumab or ravulizumab) therapy according to their usual dose and schedule.
Trial: NCT02744742
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine was administered at 20mg/m2/day on days -14 and -10.
Trial: NCT02744742
Drug: Busulfan (BU)
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
Trial: NCT02744742
Drug: Granulocyte Colony-Stimulating Factor(G-CSF)
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: G-CSF was administered at 5-10 ug/kg/day on days -17 and -10. When white blood cell is more than 20G/L, stop using G-CSF.
Trial: NCT04650984
Drug: Onfekafusp alfa
RxNorm normalized name: Onfekafusp alfa
DrugBank: Onfekafusp alfa (DB16269)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a fixed dose of L19TNF in combination with a fixed dose of doxorubicin.
Trial: NCT00863239
Drug: ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Co-administered in all arms: oral ribavirin, 200 mg capsules. Subjects with body weight \< 65 kg: 800 mg/day; Subjects with body weight 65-85 kg: 1000 mg/day; Subjects with body weight \> 85 kg: 1200 mg/day.
Trial: NCT01104935
Drug: trastuzumab monotherapy
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01104935
Drug: trastuzumab and chemotherapy
RxNorm normalized name: pertuzumab and trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03016988
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib(V) 1.3mg/m2, subcutaneously,day 1,4,8,11;
Trial: NCT03016988
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine(F) 25mg/m2, intravenously day 1-3;
Trial: NCT03016988
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine(A) 500mg/m2 for 3 days(day1-3)
Trial: NCT01830712
Drug: eptacog alfa (activated)
RxNorm normalized name: Eptacog alfa (activated)
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: A review of retrospectively longitudinal data gathered in the routine follow-up from a subset of patients who underwent EOS in studies F7HAEM/USA/3/USA and F7HAEM/USA/4/USA (NCT01561391). Data will be compiled, analysed, and reported in aggregate form.
Trial: NCT01218386
Drug: Estradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental group: estradiol valerate (Progynova, 2x2mg per day, 2mg in the morning, 2mg in the evening), orally, during 6-10 consecutive days from day 25 of the cycle onwards.~Both groups:start rFSH (Puregon®) at a dose of 150 IU GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation.